Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare progression free survival rates of metastasized
colorectal cancer patients refractory or intolerant to systemic therapy with
fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF therapy and anti-EGFR therapy (for
tumours with wild-type KRAS)); randomized for treatment with TAS-102 (standard-arm) or High
Dose Intermittent Sunitinib (700 mg once every 2 weeks). The investigators hypothesis is that
treatment with the experimental arm (sunitinib) will provide an improvement in progression
free in this patient group.